
News from Pharmacy Times
We’ve assigned a rating of Unknown factuality to Pharmacy Times. You can read more about how we’ve determined Pharmacy Times’s credibility and reliability as a news source here: https://ground.news/rating-system.
Media Bias Ratings
Do you diasgree?
Edit bias
Learn more about Media Bias Ratings.
Factuality
Learn more about Factuality Ratings
Reveal Factuality Ratings by upgrading to a Premium account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Ownership
Learn more about Ownership categories
Reveal Ownership Data by upgrading to a Vantage account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Top Pharmacy Times News

Science · United States(MedPage Today) -- The comeback story of belantamab mafodotin (Blenrep) hit a roadblock Thursday as the FDA's Oncologic Drugs Advisory Committee (ODAC) voted that the drug does not have a favorable benefit-risk profile in combination with either...See the Story
Myeloma Drug's Comeback Nixed by FDA Panel
72% Center coverage: 7 sources

Medical · PittsburghUniversity of Pittsburgh School of Public Health scientists report that seasonal influenza vaccination prevented 32.9% to 41.5% of infections in a simulated population, extending protection even to some unvaccinated residents.See the Story
Vaccinated People Aren't the only Ones Who Benefit From the Flu Shot, Study Finds
100% Center coverage: 1 sources

United States · United StatesThe FDA issued a complete response letter to Genentech indicating it cannot approve the company’s biologic license application seeking approval for glofitamab-gxbm as a treatment for relapsed or refractory diffuse large B-cell lymphoma.In its letter, the agency cited that data from the phase 3 STARGLO study failed to provide sufficient evidence to support glofitamab-gxbm (Columvi) asSee the Story
FDA Rejects Genentech’s Glofitamab-Gxbm for DLBCL, Stymied by Insufficient Evidence
100% Center coverage: 1 sources